Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ACR | P10323 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1807034 | 0.89 | CYP1A2 (0.45) | MAPK1CYP1A2ALDH1A1MEN1KMT2A | |
| SCHEMBL3760681 | 0.87 | CYP1A2 (0.44) | MAPK1CYP1A2ALDH1A1MEN1KMT2A | |
| SCHEMBL24710096 | 0.87 | CYP1A2 (0.44) | MAPK1CYP1A2ALDH1A1MEN1KMT2A | |
| SCHEMBL14067391 | 0.86 | CYP1A2 (0.42) | MAPK1CYP1A2ALDH1A1MEN1KMT2A | |
| SCHEMBL410530 | 0.85 | IDO1 (0.46) | CYP1A2ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL10044257 | 0.83 | MLYCD (0.43) | MAPK1CYP1A2ALDH1A1MEN1KMT2A | |
| SCHEMBL13887373 | 0.81 | MLYCD (0.49) | CYP1A2ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL2331928 | 0.81 | CYP1A2 (0.39) | MAPK1CYP1A2ALDH1A1MEN1KMT2A | |
| SCHEMBL20173263 | 0.79 | SCD (0.49) | MAPK1ALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL3763793 | 0.79 | ALDH1A1 (0.38) | MAPK1CYP1A2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327380-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2024-10-03 | — | — | US | disclosed |
| CN-116917279-A | BTK inhibitors | 渤健马萨诸塞州股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| EP-4192587-A1 | BTK INHIBITORS | Biogen MA Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| WO-2022032019-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| US-9827228-B2 | Opioid receptor modulators and use thereof | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2017-11-28 | — | — | US | disclosed |
| US-9827228-B2 | Opioid receptor modulators and use thereof | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2017-11-28 | — | — | US | disclosed |
| EP-2811990-B1 | MODULATORS OF EXCHANGE PROTEINS DIRECTLY ACTIVATED BY CAMP (EPACS) | UNIV TEXAS (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-2811990-B1 | MODULATORS OF EXCHANGE PROTEINS DIRECTLY ACTIVATED BY CAMP (EPACS) | UNIV TEXAS (US) | 2017-10-25 | — | — | EP | disclosed |
| WO-2017039778-A1 | OPIOID RECEPTOR MODULATORS AND USE THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2017-03-09 | — | — | WO | disclosed |
| US-20170056377-A1 | OPIOID RECEPTOR MODULATORS AND USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-03-02 | — | — | US | disclosed |
| EP-1874287-A2 | COMPOUNDS AND COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF OBESITY AND RELATED SYNDROMES | Innodia Inc. (CA) | 2008-01-09 | — | — | EP | disclosed |
| EP-1858840-A2 | ANALOGS OF 4-HYDROXYISOLEUCINE AND USES THEREOF | Innodia Inc. (CA) | 2007-11-28 | — | — | EP | disclosed |
| WO-2007107008-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF DISORDERS OF FAT METABOLISM AND OBESITY | INNODIA INC. (CA) | 2007-09-27 | — | — | WO | disclosed |
| WO-2006131836-A2 | COMPOUNDS AND COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF OBESITY AND RELATED SYNDROMES | INNODIA INC. (US) | 2006-12-14 | — | — | WO | disclosed |
| WO-2006120574-A2 | ANALOGS OF 4-HYDROXYISOLEUCINE AND USES THEREOF | INNODIA INC. (CA) | 2006-11-16 | — | — | WO | disclosed |
| US-20060223884-A1 | Compounds and compositions for use in the prevention and treatment of obesity and related syndromes | INVESTISSEMENT QUEBEC (CA) | 2006-10-05 | — | — | US | disclosed |
| EP-1704143-A1 | MALONONITRILE COMPOUND AS PESTICIDES | Sumitomo Chemical Company, Limited (JP) | 2006-09-27 | — | — | EP | disclosed |
| US-20060199853-A1 | Analogs of 4-hydroxyisoleucine and uses thereof | UNIVERSITE LOUIS PASTEUR STRASBOURG I (FR) | 2006-09-07 | — | — | US | disclosed |
| WO-2005068432-A1 | MALONONITRILE COMPOUND AS PESTICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-07-28 | — | — | WO | disclosed |
| EP-0114456-A2 | Acylated isoxazolyl ureas, their preparation, herbicidal formulations containing the same, and a herbicidal method | SHIONOGI & CO., LTD. (JP) | 1984-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223884-A1 | Compounds and compositions for use in the prevention and treatment of obesity and related syndromes | GPR119, HSD3B1, PC | MAPK1 3107/4885CYP1A2 453/4885EGFR 4653/4885 |
| US-20060199853-A1 | Analogs of 4-hydroxyisoleucine and uses thereof | GPR119, SLC2A1, SLC5A1 | MAPK1 651/4885CYP1A2 347/4885EGFR 3848/4885 |
| US-20240327380-A1 | BTK INHIBITORS | BTK, SYK, LYN | MAPK1 644/4885CYP1A2 3756/4885EGFR 207/4885 |
| US-20170056377-A1 | OPIOID RECEPTOR MODULATORS AND USE THEREOF | OPRM1, OPRK1, OPRL1 | MAPK1 2926/4885CYP1A2 425/4885EGFR 1265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.